Qin, Shukui
3 papers on CoChatORCID 0000-0002-3414-2790
Most cited papers
- Verified
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Ah Lee, M., Kitano, M., et al. (2022) · NEJM Evidence
Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments
Cited by 1,217
- Verified
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet
Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments
Cited by 1,169
- Verified
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 535
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free